Eli Lilly and Company
LLY
$1160.08
+0.01%
Eli Lilly & Co. is a global pharmaceutical company focused on neuroscience, cardiometabolic, cancer, and immunology, with key products including Mounjaro, Zepbound, and Verzenio. As a market leader in the rapidly expanding GLP-1 weight-loss and diabetes segment, Lilly has established a dominant competitive position, leveraging its first-mover advantage and robust pipeline. The current investor narrative centers on the explosive growth of its incretin franchise, recent European approval of oral weight-loss drug Foundayo, and the upcoming FDA filing for retatrutide, which is expected to further solidify its leadership. However, debates persist around valuation sustainability, competitive threats from Novo Nordisk and Pfizer, and the company's ability to maintain its growth trajectory amid capacity expansion and pricing pressures.…
LLY
Eli Lilly and Company
$1160.08
Related headlines
Investment Opinion: Should I buy LLY Today?
Based on the analysis, Eli Lilly is rated a Buy. The consensus recommendation is 'Buy' with a mean rating of 1.7, and the average analyst target of $1,315.04 implies an upside of 11.96% from the current price. The thesis is that Lilly's dominant position in the GLP-1 market, combined with a strong pipeline and accelerating revenue growth, justifies the premium valuation.
Supporting evidence includes: Q1 2026 revenue growth of 55.55% YoY, operating margin expansion to 45.56%, net margin of 37.36%, and a PEG ratio of 0.49 indicating undervaluation relative to growth. The forward PE of 24.87x is near the lower end of its historical range, suggesting the market is pricing in substantial earnings growth. Free cash flow turned positive at $3.01B, and ROE is an impressive 77.78%. These metrics collectively support the Buy rating.
Key risks that could invalidate the thesis include competitive pressures from Novo Nordisk and Pfizer, regulatory pricing actions, and execution risks in capacity expansion. The rating would be downgraded to Hold if revenue growth decelerates below 30% or if the forward PE exceeds 30x. Conversely, an upgrade to Strong Buy would be warranted if the stock pulls back to a forward PE below 20x while growth remains robust. Overall, the stock is fairly valued relative to its growth prospects, but investors should be prepared for volatility.
Sign up to view all
LLY 12-Month Price Forecast
The AI assessment is bullish, driven by exceptional growth metrics and a reasonable valuation relative to growth. The company's dominant position in the GLP-1 market and robust pipeline provide a strong foundation for continued outperformance. However, the medium confidence reflects the high expectations and competitive risks. To upgrade to high confidence, we would need to see sustained revenue growth above 50% and successful pipeline milestones. Conversely, a downgrade to neutral would occur if growth decelerates below 30% or if competitive pressures intensify.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Eli Lilly and Company's 12-month outlook, with a consensus price target around $1315.04 and implied upside of +13.4% versus the current price.
Average Target
$1315.04
0 analysts
Implied Upside
+13.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$850 - $1600
Analyst target range
Eli Lilly is covered by 29 analysts, with a consensus recommendation of 'Buy' and a mean rating of 1.7 (where 1 is Strong Buy and 5 is Sell). The average target price is $1,315.04, implying an upside of approximately 11.96% from the current price of $1,174.61. The analyst sentiment is overwhelmingly bullish, with recent actions from major firms like Citigroup, UBS, and Morgan Stanley all reiterating Buy or Overweight ratings. The target price range spans from $850.00 (low) to $1,600.00 (high), indicating a wide dispersion of expectations. The high target of $1,600 suggests analysts anticipate continued strong growth from GLP-1 drugs and pipeline successes, while the low target of $850 reflects concerns about competition, pricing pressure, or execution risks. The wide range highlights the uncertainty surrounding the stock's future performance, but the overall positive sentiment and recent upgrades suggest confidence in Lilly's long-term growth story.
Drowning in data?
Find the real signal!
Bulls vs Bears: LLY Investment Factors
Eli Lilly presents a compelling growth story with exceptional revenue acceleration, expanding margins, and a robust pipeline, but the stock's premium valuation and competitive threats create significant debate. The bull case is currently stronger, supported by strong fundamental execution and a PEG ratio below 1, but the key tension lies in whether the company can sustain its growth trajectory to justify the high multiple. If growth decelerates or competition intensifies, the stock could face a sharp de-rating. Overall, the evidence leans bullish, but investors must monitor execution and competitive dynamics closely.
Bullish
- Explosive Revenue Growth: Q1 2026 revenue surged 55.55% YoY to $19.80B, accelerating from 21.5% growth in Q1 2025, driven by the cardiometabolic segment (GLP-1 drugs). This rapid acceleration demonstrates strong market demand and successful product execution.
- Expanding Profitability: Operating margin expanded to 45.56% in Q1 2026 from 42.49% a year earlier, while net margin jumped to 37.36% from 21.68%. This operating leverage indicates efficient scaling and strong pricing power.
- Pipeline Catalyst: Retatrutide: The upcoming FDA filing for retatrutide, a next-generation weight-loss drug with superior efficacy, is expected to solidify Lilly's lead over Novo Nordisk. This pipeline strength supports long-term growth beyond current products.
- Undervalued on PEG Ratio: With a PEG ratio of 0.49, the stock trades at a discount to its growth rate, suggesting the market may be underpricing future earnings growth. This is supported by a forward PE of 24.87x, near the lower end of its historical range.
Bearish
- Rich Valuation vs. Peers: Trailing PE of 46.73x and PS of 14.81x are well above industry averages, reflecting high expectations. Any growth disappointment could lead to multiple compression.
- Intense Competition: Novo Nordisk and Pfizer are advancing their own GLP-1 drugs, with Pfizer's berobenatide in phase 3. Increased competition could pressure pricing and market share.
- Execution and Supply Risks: Rapid growth requires massive capacity expansion; any manufacturing or supply chain issues could hinder sales. The company's debt-to-equity of 1.60 indicates moderate leverage that could strain if growth slows.
- Regulatory and Pricing Pressures: Potential drug pricing reforms or reimbursement changes could impact profitability. The recent UK approval of Foundayo is positive, but regulatory hurdles remain in other markets.
LLY Technical Analysis
Eli Lilly's stock is in a strong long-term uptrend, with a 1-year price change of +60.47%, significantly outperforming the S&P 500's +18.56% over the same period. The current price of $1,174.61 sits at approximately 85% of its 52-week range (low $712.05, high $1,292.65), indicating the stock is trading near its highs, reflecting robust momentum but also potential overextension. This positioning suggests investors are optimistic about the company's growth prospects, though it also implies that much of the good news may already be priced in, leaving limited margin for error.
Beta
0.51
0.51x market volatility
Max Drawdown
-23.3%
Largest decline past year
52-Week Range
$712-$1293
Price range past year
Annual Return
+57.8%
Cumulative gain past year
| Period | LLY Return | S&P 500 |
|---|---|---|
| 1m | +3.5% | +1.0% |
| 3m | +3.1% | +1.1% |
| 6m | +17.1% | +13.8% |
| 1y | +57.8% | +19.5% |
| ytd | +7.4% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
LLY Fundamental Analysis
Eli Lilly's revenue trajectory is exceptionally strong, with Q1 2026 revenue of $19.80 billion, representing a 55.55% year-over-year growth rate, accelerating from the 21.5% growth seen in Q1 2025. This growth is driven primarily by the cardiometabolic segment, which contributed $15.76 billion in revenue, up significantly from prior quarters, while oncology and immunology also showed solid gains. The company's gross margin remains robust at 81.93%, and operating margin expanded to 45.56% in Q1 2026, reflecting operating leverage and pricing power. Net income for Q1 2026 was $7.40 billion, with a net margin of 37.36%, up from 21.68% in the year-ago quarter, demonstrating substantial profitability improvement. The balance sheet is solid, with a current ratio of 1.58 and debt-to-equity of 1.60, though leverage is moderate. Free cash flow for Q1 2026 was $3.01 billion, a significant improvement from negative FCF in Q1 2025, and ROE stands at an impressive 77.78%, indicating efficient capital deployment. The company's strong cash generation supports its growth investments and dividend, with a payout ratio of 26.09%.
Quarterly Revenue
$19.8B
2026-03
Revenue YoY Growth
+55.5%
YoY Comparison
Gross Margin
81.9%
Latest Quarter
Free Cash Flow
$13.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is LLY Overvalued?
Given Eli Lilly's strong profitability, the PE ratio is the primary valuation metric. The trailing PE is 46.73x, while the forward PE is 24.87x, indicating the market expects substantial earnings growth, with a PEG ratio of 0.49 suggesting the stock may be undervalued relative to its growth rate. Compared to the industry average, Lilly trades at a premium, with a PS ratio of 14.81x versus the sector's typical range, reflecting its superior growth and market position. Historically, the stock's PE has ranged from 27.80x to 205.08x over the past few years, and the current trailing PE of 46.73x is below the historical peak, suggesting the valuation is not at extreme levels. The forward PE of 24.87x is near the lower end of its historical band, implying that the market is pricing in significant earnings growth, which appears justified given the company's robust pipeline and market leadership.
PE
46.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 28x~76x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
35.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include moderate leverage with a debt-to-equity ratio of 1.60, though the current ratio of 1.58 provides adequate short-term liquidity. The company's heavy reliance on GLP-1 products for growth creates concentration risk; any setback in this franchise could significantly impact revenue. While free cash flow turned positive, the company's aggressive investment in capacity expansion and R&D (Q1 R&D of $3.51B) could pressure cash flows if growth slows. Earnings volatility is evident from the historical net margin fluctuations, but recent trends show improvement. The payout ratio of 26.09% is conservative, but dividend growth may lag if cash is redirected to growth initiatives.
Market risks include valuation compression potential, as the trailing PE of 46.73x is well above the industry average, leaving little room for error. Competitive threats from Novo Nordisk and Pfizer could erode market share and pricing power. Regulatory risks, such as drug pricing reforms or reimbursement changes, could impact profitability. The stock's beta of 0.506 suggests lower correlation to the market, but it is still sensitive to sector rotation and healthcare policy news. Recent news highlights the competitive landscape, with Pfizer's berobenatide and Viking's progress, indicating that Lilly's dominance is not guaranteed.
In a worst-case scenario, a combination of factors—such as a major clinical trial failure, aggressive competition leading to price cuts, or regulatory actions—could trigger a significant sell-off. The 52-week low of $712.05 represents a potential downside of -39.4% from the current price of $1,174.61. Historical max drawdown of -23.31% suggests that even in moderate downturns, losses could be substantial. If the market re-rates the stock to a more typical pharma PE of 20x, the price could fall to around $500, implying a -57% decline. Thus, investors face meaningful downside risk if the growth narrative falters.
FAQ
The key risks include: 1) Competitive pressure from Novo Nordisk and Pfizer, which could erode market share and pricing power. 2) Regulatory risks, such as drug pricing reforms or reimbursement changes, which could impact profitability. 3) Execution risks in scaling up manufacturing capacity to meet demand. 4) Valuation risk, as the stock trades at a premium to peers, leaving little room for error. The most severe risk is a clinical trial failure for a key pipeline drug like retatrutide, which could trigger a sharp sell-off.
The 12-month forecast is positive, with a base case target of $1,200-$1,350 (50% probability), a bull case of $1,400-$1,600 (30% probability), and a bear case of $850-$1,000 (20% probability). The most likely scenario is the base case, assuming continued strong growth in the GLP-1 franchise and successful pipeline progress. The stock is expected to trade around the analyst average target of $1,315, implying an upside of about 12% from the current price.
Based on trailing earnings, LLY appears overvalued with a PE of 46.73x, well above the industry average. However, on a forward basis, the PE of 24.87x is more reasonable, and the PEG ratio of 0.49 suggests the stock is undervalued relative to its expected growth. The PS ratio of 14.81x is also high, but this is justified by the company's superior growth and profitability. Overall, the market is pricing in substantial future earnings growth, which seems warranted given the company's pipeline and market position.
Eli Lilly is a good buy for investors seeking exposure to the high-growth GLP-1 market, given its dominant position and strong pipeline. The stock offers an 11.96% upside to the average analyst target of $1,315, and the PEG ratio of 0.49 suggests it is undervalued relative to its growth rate. However, the trailing PE of 46.73x indicates high expectations, and any disappointment could lead to significant downside. It is a good buy for those with a long-term horizon and high risk tolerance, but not for conservative investors.
LLY is more suitable for long-term investment, given its strong growth prospects and pipeline. The stock's beta of 0.506 indicates lower volatility than the market, but it can still experience significant swings. The company's dividend yield is low at 0.56%, so income investors may look elsewhere. For long-term investors, a minimum holding period of 3-5 years is recommended to fully capture the growth from GLP-1 drugs and pipeline catalysts. Short-term trading is possible but risky due to high valuation and sensitivity to news.
